No headlines found.
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Tue, 6-Jan 7:30 AM ET)
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
PRNewswire (Tue, 16-Dec 11:53 AM ET)
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Globe Newswire (Mon, 10-Nov 4:15 PM ET)
Globe Newswire (Thu, 6-Nov 11:00 AM ET)
Globe Newswire (Wed, 29-Oct 7:30 AM ET)
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Prokidney Corp. - Class A trades on the NASDAQ stock market under the symbol PROK.
As of January 23, 2026, PROK stock price declined to $2.17 with 193,307 million shares trading.
PROK has a beta of 2.76, meaning it tends to be more sensitive to market movements. PROK has a correlation of 0.05 to the broad based SPY ETF.
PROK has a market cap of $307.15 million. This is considered a Small Cap stock.
Last quarter Prokidney Corp. - Class A reported $217,000 in Revenue and -$.12 earnings per share. This beat revenue expectation by $172,750 and exceeded earnings estimates by $.01.
In the last 3 years, PROK traded as high as $14.19 and as low as $.46.
The top ETF exchange traded funds that PROK belongs to (by Net Assets): VXF, SCHA, SCHB.
PROK has outperformed the market in the last year with a return of +29.9%, while the SPY ETF gained +15.1%. However, in the most recent history, PROK shares have underperformed the stock market with its stock returning -31.3% in the last 3 month period and -8.1% for the last 2 week period, while SPY has returned +3.7% and +0.2%, respectively.
PROK support price is $2.08 and resistance is $2.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PROK shares will trade within this expected range on the day.
